

# COVID-Q: validation of the first COVID-19 questionnaire based on patient-rated symptom gravity

Giacomo Spinato<sup>1</sup>, Cristoforo Fabbris<sup>1</sup>, Federica Conte<sup>2</sup>, Anna Menegaldo<sup>1</sup>, Leonardo Franz<sup>1</sup>, Piergiorgio Gaudioso<sup>1</sup>, Francesco Cinetto<sup>3</sup>, Carlo Agostini<sup>3</sup>, Giulio Costantini<sup>2</sup>, and Paolo Boscolo-Rizzo<sup>4</sup>

<sup>1</sup>Università degli Studi di Padova Dipartimento di Neuroscienze

<sup>2</sup>Università degli Studi di Milano-Bicocca

<sup>3</sup>Università degli Studi di Padova

<sup>4</sup>Azienda Sanitaria Universitaria Integrata di Trieste


May 19, 2021

## Abstract

**Objectives** The aim of the present study is to develop and validate the COVID-Q, a novel symptom questionnaire specific for COVID-19 patients, to provide a comprehensive and standard clinical evaluation. A secondary goal of the present study was to evaluate the performance of the COVID-Q in identifying subjects at higher risk of being tested positive for COVID-19. **Material and methods** 460 subjects (230 COVID-19 cases and 230 healthy controls), answered the COVID-Q. Parallel Analysis and Principal Component Analysis were used to identify clusters of items measuring the same dimension. The IRT-based analyses evaluated the functioning of item categories, the presence of clusters of local dependence among items, item fit within the model and model fit to the data. **Results** Parallel analysis suggested the extraction of six components, which corresponded to as many clinical presentation patterns: asthenia, influenza-like symptoms, ear and nose symptoms, breathing issues, throat symptoms, and anosmia/ageusia. The final IRT models retained 27 items as significant for symptom assessment. The total score on the questionnaire was significantly associated with positivity to the molecular SARS-CoV-2 test. Subjects with multiple symptoms were significantly more likely to be affected by COVID-19 ( $p < .001$ ). Older age and male gender also represented risk factors. None of the examined comorbidities had a significant association with COVID-19 diagnosis. **Conclusion** The application of the novel COVID-Q to everyday clinical practice may help identifying subjects who are likely to be affected by COVID-19 and address them to a nasopharyngeal swab in order to achieve an early diagnosis.

## Hosted file

COVID-Q\_-\_Manuscript\_16-05-21.docx available at <https://authorea.com/users/414638/articles/522631-covid-q-validation-of-the-first-covid-19-questionnaire-based-on-patient-rated-symptom-gravity>



### Hosted file

COVID-Q - Tables 16-05-21.docx available at <https://authorea.com/users/414638/articles/522631-covid-q-validation-of-the-first-covid-19-questionnaire-based-on-patient-rated-symptom-gravity>